Developer docs
API playgroundTry for free, no card

Search company profiles

Start Codon

Full company profile

uuid00091u5

Namestring
Start Codon
Legal namestring
Start Codon
Websiteurl
startcodon.co
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Start Codon is a Cambridge-based life sciences venture builder and accelerator founded in 2018 that identified, funded and supported early-stage disruptive biotech innovations originating from across the United Kingdom. The entity operated as a subsidiary of Cambridge Innovation Capital, backed by a founding-investor syndicate comprising CIC (lead), Genentech, Babraham Research Campus, Dr Ian Tomlinson (former co-founder/CSO of Domantis, sold to GSK for $454 million) and Meltwind Advisory on behalf of Dr Jonathan Milner (founder of Abcam). Over a 2018-2025 operating window Start Codon raised over £50 million and built a portfolio of 28 companies spanning oncology therapeutics (Awen Oncology, Coding Bio, NK:IO, Spirea), CNS and neurodegenerative disease (CoSyne Therapeutics, TRIMTECH Therapeutics), functional genomics and multiomics (Enhanc3D Genomics, Tagomics), MedTech and diagnostics (Octiocor, VentriPace Medical, Phorest Diagnostics, Semarion, Verinnogen), digital health (Adora, Emm), RNA biology and gene therapy (Drishti Discoveries, RevoNA, Spliceor), manufacturing biologics (Erebagen, StemBond Technologies), and animal health and infection prevention (ArkVax, Proxximos).

Start Codon's core product was its accelerator program, which combined equity investment with mentorship, lab space at Babraham Research Campus, and curated access to its founding-investor network. Several portfolio companies leveraged AI/ML approaches — HotHouse Therapeutics applied AI-enabled design to a plant expression platform, RevoNA integrated machine learning into its RNA discovery engine, and Coding Bio used high-throughput candidate screening — but AI was a portfolio-level rather than firm-level capability. The accelerator generated returns through equity stakes in portfolio companies rather than through subscription or licensing revenue, and operated with a lean team of 1-10 employees under CEO Jason Mellad and co-founder/coo Daniel Rooke. Its distribution model was direct equity investment sourced through its founding-investor network and the broader Cambridge / UK Golden Triangle life sciences ecosystem.

In 2025 Start Codon was absorbed into Cambridge Innovation Capital, completing its lifecycle as an independent accelerator; the entity no longer operates as a standalone brand and its 28 portfolio companies are managed directly within CIC's portfolio. Absent the absorption, the venture builder's competitive position rested on ecosystem lock-in to Cambridge and the Babraham research cluster, the Genentech pharmaceutical BD channel, and the credibility of Tomlinson and Milner as founding advisors.

Short descriptiontext

Start Codon was a Cambridge-based life sciences venture builder and accelerator, founded in 2018 and absorbed into Cambridge Innovation Capital in 2025, that raised over £50 million and invested in 28 early-stage UK biotech companies spanning therapeutics, diagnostics, MedTech and digital health.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences accelerator, venture builder, biotech investments, early-stage startups, life sciences funding
Industry1 code
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
Product category
Biotech Accelerator / Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Accelerator and Venture Capital Returns
TypeSubscription Recurring
Description

Start Codon operates as a venture builder and accelerator, generating returns through equity stakes in its portfolio companies. It was absorbed into Cambridge Innovation Capital after raising over £50 million. Start Codon identifies and invests in early-stage disruptive life sciences innovations, providing funding and operational support in exchange for equity.

cic.vc
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Start Codon is a Cambridge-based life sciences venture builder and accelerator that identifies, funds, and supports early-stage disruptive life sciences innovations created by teams from across the UK. It provides portfolio companies with equity investment, mentorship, strategic guidance, and access to its network of founding investors and the Cambridge research ecosystem. The entity has invested in 28 early-stage biotech companies before being absorbed into Cambridge Innovation Capital.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Start Codon is a Cambridge-based life sciences accelerator and venture builder that has invested in 28 early-stage disruptive innovations created by exceptional teams from across the UK. The accelerator's core offering is its program, which identifies, funds, and supports biotech startups. The portfolio spans diverse therapeutic areas and technologies including digital health (Adora, Emm), oncology therapeutics (Awen Oncology, Coding Bio, NK:IO), brain disease (CoSyne Therapeutics), gene therapy (Drishti Discoveries), functional genomics (Enhanc3D Genomics), multiomics (Tagomics), protein degradation therapeutics (TRIMTECH Therapeutics), medical devices (Octiocor, VentriPace Medical, Verinnogen), diagnostics (Phorest Diagnostics, Semarion), and biotech platform technologies (HotHouse Therapeutics, Indegra Therapeutics, Erebagen, RevoNA, Spirea, Spliceor, StemBond Technologies), along with animal health (ArkVax) and infection prevention (Proxximos). Start Codon itself is not a product company but rather an investment and mentorship vehicle that builds and supports these individual portfolio companies.

Product and service1 record
1Start Codon Accelerator Program
CategoryLife Sciences Accelerator / Venture Builder
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeOthers
Description

TRIMTECH Therapeutics is a portfolio company of Start Codon occupying space at Babraham Research Campus. The company is a UK biotech developing small molecule therapies for neurodegenerative diseases like Alzheimer's and Huntington's.

2Tagomics Ltd.
Strategic tierMinorTypeOthers
Description

Tagomics Ltd. is a portfolio company of Start Codon occupying space at Babraham Research Campus. Tagomics is a Cambridge-based biomarker discovery company.

pharmiweb.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

BioGenerator is the venture creation arm of BioSTL in St. Louis, building and funding early-stage life sciences companies from regional academic research. Comparable venture-builder model for life sciences, though US-focused rather than UK-focused.

TypeEmerging player
Description

Pillar VC's biotech program supports founder-led life sciences companies from inception in the Boston/New England ecosystem. Comparable in providing early-stage capital and venture-building support to biotech founders, though broader than pure therapeutics.

TypeDirect peer
Description

Apollo Therapeutics is a UK-based venture builder that translates academic research from Cambridge, Imperial, and UCL into therapeutic companies. Direct peer with shared Cambridge roots and a similar model of building biotechs from university IP.

TypeDirect peer
Description

IndieBio is the world's largest life sciences accelerator, operating cohort-based programs with equity investment in early-stage biotech and healthtech founders. Directly comparable as an accelerator-deploying-equity model targeting disruptive life sciences, though IndieBio operates in San Francisco/New York versus Start Codon's UK base.

TypeBroad incumbent
Description

Atlas Venture is a Boston-based early-stage biotech-focused venture firm that builds companies from inception. Comparable in forming and funding therapeutic biotech startups, though operating at a much larger AUM and not strictly an accelerator.

TypeDirect peer
Description

Mission BioCapital is an early-stage biotech venture firm that partners with founders at company formation, providing both capital and operational support. Directly comparable venture-builder model for nascent life sciences companies.

7Petri
TypeDirect peer
Description

Petri is a Boston-based biotech accelerator and venture builder that funds and supports early-stage life sciences companies from ideation through seed. Highly comparable in its venture-builder approach and dedicated operating partner model for nascent biotech teams.

8Cambridge Enterprise Ventures
TypeDirect peer
Description

Cambridge Enterprise Ventures is the University of Cambridge's own seed/Series A investment arm, supporting Cambridge spin-outs. Direct peer operating in the same Cambridge ecosystem with overlapping deal flow and co-investment activity (e.g., Semarion round).

9Merck KGaA / M Ventures
TypeBroad incumbent
Description

M Ventures is the corporate venture capital arm of Merck KGaA, investing globally in early-stage life sciences including therapeutics, diagnostics, and digital health. Comparable strategic CVC model backing disruptive life sciences, but as part of a much larger pharma conglomerate.

TypeEmerging player
Description

CRUK's Commercial Partnerships team creates and funds early-stage oncology companies from UK academic research. Comparable in funding translational life sciences from UK institutions, though focused specifically on oncology rather than the broad therapeutic mix Start Codon targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Start Codon

Biotech Accelerator / Venture Capitalstartcodon.co

Start Codon was a Cambridge-based life sciences venture builder and accelerator, founded in 2018 and absorbed into Cambridge Innovation Capital in 2025, that raised over £50 million and invested in 28 early-stage UK biotech companies spanning therapeutics, diagnostics, MedTech and digital health.

What Start Codon does

Start Codon is a Cambridge-based life sciences venture builder and accelerator founded in 2018 that identified, funded and supported early-stage disruptive biotech innovations originating from across the United Kingdom. The entity operated as a subsidiary of Cambridge Innovation Capital, backed by a founding-investor syndicate comprising CIC (lead), Genentech, Babraham Research Campus, Dr Ian Tomlinson (former co-founder/CSO of Domantis, sold to GSK for $454 million) and Meltwind Advisory on behalf of Dr Jonathan Milner (founder of Abcam). Over a 2018-2025 operating window Start Codon raised over £50 million and built a portfolio of 28 companies spanning oncology therapeutics (Awen Oncology, Coding Bio, NK:IO, Spirea), CNS and neurodegenerative disease (CoSyne Therapeutics, TRIMTECH Therapeutics), functional genomics and multiomics (Enhanc3D Genomics, Tagomics), MedTech and diagnostics (Octiocor, VentriPace Medical, Phorest Diagnostics, Semarion, Verinnogen), digital health (Adora, Emm), RNA biology and gene therapy (Drishti Discoveries, RevoNA, Spliceor), manufacturing biologics (Erebagen, StemBond Technologies), and animal health and infection prevention (ArkVax, Proxximos).

Start Codon's core product was its accelerator program, which combined equity investment with mentorship, lab space at Babraham Research Campus, and curated access to its founding-investor network. Several portfolio companies leveraged AI/ML approaches — HotHouse Therapeutics applied AI-enabled design to a plant expression platform, RevoNA integrated machine learning into its RNA discovery engine, and Coding Bio used high-throughput candidate screening — but AI was a portfolio-level rather than firm-level capability. The accelerator generated returns through equity stakes in portfolio companies rather than through subscription or licensing revenue, and operated with a lean team of 1-10 employees under CEO Jason Mellad and co-founder/coo Daniel Rooke. Its distribution model was direct equity investment sourced through its founding-investor network and the broader Cambridge / UK Golden Triangle life sciences ecosystem.

In 2025 Start Codon was absorbed into Cambridge Innovation Capital, completing its lifecycle as an independent accelerator; the entity no longer operates as a standalone brand and its 28 portfolio companies are managed directly within CIC's portfolio. Absent the absorption, the venture builder's competitive position rested on ecosystem lock-in to Cambridge and the Babraham research cluster, the Genentech pharmaceutical BD channel, and the credibility of Tomlinson and Milner as founding advisors.

Start Codon firmographics

Firmographics
Name
Start Codon
Legal name
Start Codon
Website
https://startcodon.co
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
1–10 employees
Short description
Start Codon was a Cambridge-based life sciences venture builder and accelerator, founded in 2018 and absorbed into Cambridge Innovation Capital in 2025, that raised over £50 million and invested in 28 early-stage UK biotech companies spanning therapeutics, diagnostics, MedTech and digital health.
Ownership category
akta.pro rank

Start Codon industry classification

Industry
Product category
Biotech Accelerator / Venture Capital
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Life sciences accelerator
  • Venture builder
  • Biotech investments
  • Early-stage startups
  • Life sciences funding

Where Start Codon is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Start Codon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Accelerator and Venture Capital Returns: Start Codon operates as a venture builder and accelerator, generating returns through equity stakes in its portfolio companies. It was absorbed into Cambridge Innovation Capital after raising over £50 million. Start Codon identifies and invests in early-stage disruptive life sciences innovations, providing funding and operational support in exchange for equity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Start Codon product offering

Product offering

Core offering

Start Codon is a Cambridge-based life sciences venture builder and accelerator that identifies, funds, and supports early-stage disruptive life sciences innovations created by teams from across the UK. It provides portfolio companies with equity investment, mentorship, strategic guidance, and access to its network of founding investors and the Cambridge research ecosystem. The entity has invested in 28 early-stage biotech companies before being absorbed into Cambridge Innovation Capital.

Product overview

Start Codon is a Cambridge-based life sciences accelerator and venture builder that has invested in 28 early-stage disruptive innovations created by exceptional teams from across the UK. The accelerator's core offering is its program, which identifies, funds, and supports biotech startups. The portfolio spans diverse therapeutic areas and technologies including digital health (Adora, Emm), oncology therapeutics (Awen Oncology, Coding Bio, NK:IO), brain disease (CoSyne Therapeutics), gene therapy (Drishti Discoveries), functional genomics (Enhanc3D Genomics), multiomics (Tagomics), protein degradation therapeutics (TRIMTECH Therapeutics), medical devices (Octiocor, VentriPace Medical, Verinnogen), diagnostics (Phorest Diagnostics, Semarion), and biotech platform technologies (HotHouse Therapeutics, Indegra Therapeutics, Erebagen, RevoNA, Spirea, Spliceor, StemBond Technologies), along with animal health (ArkVax) and infection prevention (Proxximos). Start Codon itself is not a product company but rather an investment and mentorship vehicle that builds and supports these individual portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Start Codon Accelerator Program

Companies that use Start Codon

Customer profile

Segments1 record

Ideal customer profiles1 record

Start Codon technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Start Codon partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • TRIMTECH TherapeuticsminorOthersTRIMTECH Therapeutics is a portfolio company of Start Codon occupying space at Babraham Research Campus. The company is a UK biotech developing small molecule therapies for neurodegenerative diseases like Alzheimer's and Huntington's.
  • Tagomics Ltd.minorOthersTagomics Ltd. is a portfolio company of Start Codon occupying space at Babraham Research Campus. Tagomics is a Cambridge-based biomarker discovery company.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Start Codon competitors and assessment

Company assessment

Regional players

  • BioGenerator: BioGenerator is the venture creation arm of BioSTL in St. Louis, building and funding early-stage life sciences companies from regional academic research. Comparable venture-builder model for life sciences, though US-focused rather than UK-focused.

Emerging players

  • Pillar VC: Pillar VC's biotech program supports founder-led life sciences companies from inception in the Boston/New England ecosystem. Comparable in providing early-stage capital and venture-building support to biotech founders, though broader than pure therapeutics.
  • Cancer Research UK (Commercial Partnerships): CRUK's Commercial Partnerships team creates and funds early-stage oncology companies from UK academic research. Comparable in funding translational life sciences from UK institutions, though focused specifically on oncology rather than the broad therapeutic mix Start Codon targets.

Direct peers

  • Apollo Therapeutics: Apollo Therapeutics is a UK-based venture builder that translates academic research from Cambridge, Imperial, and UCL into therapeutic companies. Direct peer with shared Cambridge roots and a similar model of building biotechs from university IP.
  • IndieBio (SOSV): IndieBio is the world's largest life sciences accelerator, operating cohort-based programs with equity investment in early-stage biotech and healthtech founders. Directly comparable as an accelerator-deploying-equity model targeting disruptive life sciences, though IndieBio operates in San Francisco/New York versus Start Codon's UK base.
  • Mission BioCapital: Mission BioCapital is an early-stage biotech venture firm that partners with founders at company formation, providing both capital and operational support. Directly comparable venture-builder model for nascent life sciences companies.
  • Petri: Petri is a Boston-based biotech accelerator and venture builder that funds and supports early-stage life sciences companies from ideation through seed. Highly comparable in its venture-builder approach and dedicated operating partner model for nascent biotech teams.
  • Cambridge Enterprise Ventures: Cambridge Enterprise Ventures is the University of Cambridge's own seed/Series A investment arm, supporting Cambridge spin-outs. Direct peer operating in the same Cambridge ecosystem with overlapping deal flow and co-investment activity (e.g., Semarion round).

Broad incumbents

  • Atlas Venture: Atlas Venture is a Boston-based early-stage biotech-focused venture firm that builds companies from inception. Comparable in forming and funding therapeutic biotech startups, though operating at a much larger AUM and not strictly an accelerator.
  • Merck KGaA / M Ventures: M Ventures is the corporate venture capital arm of Merck KGaA, investing globally in early-stage life sciences including therapeutics, diagnostics, and digital health. Comparable strategic CVC model backing disruptive life sciences, but as part of a much larger pharma conglomerate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Start Codon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Start Codon leadership team

Management profile

Number of profiles

Profiles2 records

Start Codon funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Start Codon M&A and investment

M&A and investment

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Start Codon

What does Start Codon do?

Start Codon is a Cambridge-based life sciences venture builder and accelerator that identifies, funds, and supports early-stage disruptive life sciences innovations created by teams from across the UK. It provides portfolio companies with equity investment, mentorship, strategic guidance, and access to its network of founding investors and the Cambridge research ecosystem. The entity has invested in 28 early-stage biotech companies before being absorbed into Cambridge Innovation Capital.

Is Start Codon a public or private company?

Start Codon is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Start Codon founded?

Start Codon was founded in 2018. It employs 1 to 10 people.

Where is Start Codon based?

Start Codon is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Start Codon make money?

One revenue line is on record: accelerator and Venture Capital Returns.

Who are Start Codon's main competitors?

BioGenerator is listed as a regional player. Emerging players are Pillar VC and Cancer Research UK (Commercial Partnerships). Direct peers are Apollo Therapeutics, IndieBio (SOSV), Mission BioCapital, Petri and Cambridge Enterprise Ventures. Broad incumbents are Atlas Venture and Merck KGaA / M Ventures.

Does Start Codon have an API?

No public API is recorded for Start Codon.

What industry is Start Codon in?

Start Codon's product category is Biotech Accelerator / Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyTRIMTECH extends seed round to $47M for protein degradation drugsTRIMTECH Therapeutics raised an additional $14 million, bringing its total seed financing to $47 million. The funding, led by Johnson & Johnson Innovation and BGF, supports development of small molecule drugs that degrade toxic protein aggregates linked to neurodegenerative diseases. The company has not disclosed a lead indication or clinical timeline.News-MedicalSemarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoptionSemarion raised $3.8 million led by Parkwalk to scale its SemaCyte cell assay platform. The funding will expand manufacturing and field support, with adoption by top 10 pharma companies and collaborations with Revvity and SPT Labtech.Business WeeklyCambridge Innovation Capital to curate Start Codon futureStart Codon, a Cambridge accelerator, was absorbed into Cambridge Innovation Capital after its £15m fund raised over £50m. The venture had invested in 28 companies, and CIC will continue to monitor the portfolio.Tech.euAddressing foundational bottlenecks in drug discovery, Cambridge spin-out lands £2.14 millionCambridge spin-out Semarion has secured a £2.14 million seed round led by Parkwalk Advisors, with participation from University of Cambridge Seed Funds, Martlet Capital and angel investors. The funding will fund commercial development of its SemaCyte cell assaying platform and team expansion, including hiring scientists and engineers. The company previously received pre-seed support from venture builder Start Codon.TechStartupsStart Codon secures $20 million in funding for its venture fund to invest in life science and healthcare startupsStart Codon closed $20 million in funding for its Start Codon Fund I LP, with Novartis and Cambridge Innovation Capital as limited partners. The fund will provide seed funding, business support, and access to facilities for life science startups, with Novartis offering mentoring and partnership opportunities. Start Codon plans to invest in up to 50 companies over five years.FinSMEsStart Codon Closes £15M Venture FundStart Codon, a UK life science accelerator, closed its first venture fund at £15M, with Novartis and Cambridge Innovation Capital as limited partners. The fund will provide up to £250K seed funding and support for startups, with plans to invest in up to 50 companies over five years.News-MedicalStart Codon and One Nucleus join hands to enable success of UK life science clusterStart Codon and One Nucleus announced a partnership to support UK life science start-ups in the accelerator program. One Nucleus will provide gold membership benefits, including a company profile and discounted training, for 12 months. Start Codon CEO Dr Jason Mellad will speak at the One Nucleus Genesis conference on December 11.FinSMEsAcceleration Program Start Codon Launches With FundingStart Codon, a UK-based life science accelerator, launched with undisclosed funding from Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, and others. It will invest up to £250K per startup and support up to 50 companies over five years, with the first cohort of five companies now being recruited.